BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 276 filers reported holding BIO-TECHNE CORP in Q4 2016. The put-call ratio across all filers is - and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $2,423,000 | -47.2% | 11,621 | -49.7% | 0.08% | -46.9% |
| Q1 2019 | $4,585,000 | +37.2% | 23,091 | 0.0% | 0.14% | +17.9% |
| Q4 2018 | $3,342,000 | -40.1% | 23,091 | -15.5% | 0.12% | -29.7% |
| Q3 2018 | $5,576,000 | +38.0% | 27,320 | 0.0% | 0.18% | +48.3% |
| Q2 2018 | $4,042,000 | -2.4% | 27,320 | -0.5% | 0.12% | +4.4% |
| Q1 2018 | $4,142,000 | +4.8% | 27,450 | -10.1% | 0.11% | +17.7% |
| Q4 2017 | $3,954,000 | -12.9% | 30,518 | -18.7% | 0.10% | -16.5% |
| Q3 2017 | $4,539,000 | +2.9% | 37,544 | 0.0% | 0.12% | -8.7% |
| Q2 2017 | $4,411,000 | +7.0% | 37,544 | -7.4% | 0.13% | +8.6% |
| Q1 2017 | $4,121,000 | +112.2% | 40,545 | +114.7% | 0.12% | +107.1% |
| Q4 2016 | $1,942,000 | -6.1% | 18,884 | 0.0% | 0.06% | +9.8% |
| Q3 2016 | $2,068,000 | +12.9% | 18,884 | +16.2% | 0.05% | +18.6% |
| Q2 2016 | $1,832,000 | +3.3% | 16,245 | -13.5% | 0.04% | +10.3% |
| Q1 2016 | $1,774,000 | +8347.6% | 18,771 | +8132.9% | 0.04% | – |
| Q4 2015 | $21,000 | 0.0% | 228 | 0.0% | 0.00% | – |
| Q3 2015 | $21,000 | – | 228 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |